Market Newsdesk

QuantuMDx diagnostic test for SARS-CoV-2 remains suitable for the detection of all discovered variants, including VUI-202012/01

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx Group Limited (“QuantuMDx”), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2.

The UK COVID Genomics Consortium and Public Health England have identified a new strain of SARS-CoV-2 which is characterised by multiple spike gene variants. The new strain known as VUI-202012/01 or lineage B.1.1.7 appears to be significantly more transmissible than other circulating linages and there are reports that some diagnostic tests may be affected.

QuantuMDx continually monitors genomic sequences deposited to the NCBI and GISAID databases as part of post market surveillance. Analysis of VUI-202012/01 genomes shows that none of the variants interfere with QuantuMDx’s three target QMDx SARS-CoV-2 test. 

The high performance QuantuMDx SARS-CoV-2 assay has been proven against seven separate sample cohorts including independent evaluations from FIND, several hospitals and UK Department of Health and Social Care. Aggregated across cohorts, totalling over 800 samples, clinical sensitivity was shown to be 98.9% and specificity 99.8%.

Jonathan O’Halloran, Chief Executive, QuantuMDx, said:

“At the start of the outbreak, we anticipated the emergence of new strains as the pandemic progressed and designed our assay to target three different genomic regions of SARS-CoV-2.  We can confirm that this new strain of virus will not affect our assay which maintains its high level of sensitivity in the UK and worldwide. We continue to work with regional, national, and international health authorities as we continue efforts to deliver high quality diagnostics for COVID-19.

“Q-POC^TM, our 30 min swab to result PCR point-of-care device, is nearing launch and will run an assay targeting the same three loci as the QuantuMDx SARS-CoV-2 RT-PCR Detection Assay. We are already experiencing great demand for this incredibly powerful device and want to assure our customers that our test will work across all strains represented in the online SARS-CoV-2 genome databases.”

About QuantuMDx:

QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com

For media enquiries:

Debra Daglish, Marketing Communications Manager, QuantuMDx Group, 0870 803 1234

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, 0203 709 5700/ [email protected]

For investor enquiries:

Financial Adviser: WG Partners LLP; David Wilson (020 3705 9315), Nigel Barnes (020 3705 9318), Claes Spång (020 3705 9317)

RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial.

Based on the company’s ongoing discussions with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, a major funding partner for the program, BioCryst expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.

“We are encouraged by the first patient data with galidesivir and the growing body of evidence that galidesivir could be an important broad-spectrum antiviral. We appreciate the government’s continued investment to investigate galidesivir as a biodefense drug,” said Jon Stonehouse, chief executive officer of BioCryst.

BioCryst is engaged in ongoing discussions with NIAID to define specific further galidesivir studies that NIAID would support.

Part 1 Trial Design


Part 1 of the trial enrolled 24 hospitalized adults diagnosed with moderate to severe COVID-19 confirmed by PCR. Three cohorts of eight patients were randomized to receive intravenous galidesivir (n=6) or placebo (n=2) every 12 hours for seven days.

Each dosing regimen began with a single 10 mg/kg or 20 mg/kg loading dose, followed by a maintenance dose of 2 mg/kg or 5 mg/kg administered twice daily. The three dosing regimens evaluated were 10 mg/kg then 2 mg/kg (cohort 1), 10 mg/kg then 5 mg/kg (cohort 2) and 20 mg/kg then 5 mg/kg (cohort 3).

The trial was conducted in Brazil under a U.S. investigational new drug application. The protocol also was approved by the Agência Nacional de Vigilância Sanitária (ANVISA) and the Brazilian National Ethics Committee (CONEP).

Part 1 Results


The primary objective of part 1 of the dose-ranging study was to evaluate the safety of galidesivir. No safety signals were identified, and all three dose levels were equally safe.

Secondary objectives were to evaluate the effect of galidesivir on the clinical course of COVID-19 and on SARS-CoV-2 infection in the respiratory tract.

Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner.
        
A separate study of galidesivir in a COVID-19 animal model showed that early administration of galidesivir reduced SARS-CoV-2 viral burden in lung tissue (1.4-1.6 log lower tissue viral burden) and was associated with a significant reduction in damage to lung tissue, compared to vehicle control treated animals. These results suggest that early antiviral treatment of SARS-CoV-2 infection may protect against developing severe COVID-19 lung disease.

NIAID is a major funding partner of the galidesivir program under contracts 75N93020C00055 and HHSN272201300017C.

About Galidesivir (BCX4430)

Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of Marburg virus disease. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including, Ebola, Marburg, Yellow Fever and Zika viruses. Galidesivir has also demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including coronaviruses, filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, and flaviviruses. BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst’s first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company’s website at www.biocryst.com.

Forward-Looking Statements 

This press release contains forward-looking statements, including statements regarding BioCryst’s plans and expectations for its galidesivir development program. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results and developments of such program to be materially different from any future results or developments expressed or implied by the forward-looking statements. These statements reflect our current views and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: NIAID’s ability to determine not to exercise available options under its contracts with BioCryst or to terminate such contracts at any time, causing BioCryst not to realize the aggregate value of the contracts; funding for galidesivir under government contracts is dependent on the progress toward, and the achievement of, developmental milestones; the ongoing COVID-19 pandemic could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described herein or in the documents BioCryst files periodically with the Securities and Exchange Commission; developing and manufacturing any product candidate, including galidesivir, may take longer or may be more expensive than planned; funding for the continued development and manufacture of galidesivir may not be available; ongoing and future preclinical and clinical studies with galidesivir may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates, including galidesivir; BioCryst may not advance human clinical trials with product candidates, including galidesivir, as expected; and the FDA, or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose a clinical hold with respect to such product candidates, or may withhold market approval for product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s forward-looking statements.

BCRXW

Contacts:


John Bluth
+1 919 859 7910
[email protected]

Catherine Collier Kyroulis
+1 917 886 5586
[email protected] 

 

Montreal, Dec. 22, 2020 (GLOBE NEWSWIRE) — Montreal, Quebec, December 22, 2020 – Aya Gold & Silver Inc. (TSX: AYA) (“Aya” or the “Corporation”) is pleased to provide a review of operations since assuming control in May 2020 including a recap of the 2020 top silver intercepts previously released from its Zgounder Silver Mine in the Kingdom of Morocco.

Strong Finish to 2020 Drill Exploration Program

Since September 2020, approximately 17,465 metres of new drilling have been completed, with a focus on expanding the silver resource at depth and along strike to the east and to the west at Zgounder. A total of 16 diamond drill hole (“DDH”) high-grade silver intercepts were announced since September 2020, confirming high-grade silver mineralization along strike and at depth below the current mining operations – up to the granite contact. These results secure Zgounder’s position globally as a top-tier, high-grade, pure-play silver mine. In addition to providing seven of Zgounder’s top 50 all-time drill intersections, the drill exploration program yielded two of the top 50 global primary- silver intercepts of 2020 including an industry-best of 9,346 g/t Ag over 4.00 metres – below the current Zgounder mining operations.

The Corporation has subsequently expanded its original 2020 drill exploration program from 15,000 meters to 19,000 meters.

Benoit La Salle, President and CEO, commented: “It has been a very busy year for the Aya operation and exploration teams, compounded further by global events related to the pandemic. Aya has completed a maintenance turnaround plan and is focused on growing the resource outside of the current mining operations. Our exploration team successfully completed and expanded our initial drill exploration program ahead of plan and expanded it to with over 8 surface and underground drills on site. Phase 2 drilling is scheduled to begin early next year with an objective of meaningfully growing our resource over the next 12 months. Our financial position remains very strong, with approximately C$42 million in cash.

None of this would have been possible without the expertise and commitment of our loyal employees and contractors. In this transition year, their close teamwork has been critical to delivering on our work program and maintaining a safe and efficient work environment. We are also grateful for the strong support from the Kingdom of Morocco and all of our stakeholders.”

The table below showcases Zgounder’s 2020 top drill intercepts ranked by grade-thickness:

Table 1 – Top 2020 Intercepts from Zgounder by Grade-Thickness

Location	Hole No.	From (m)	To (m)	Length1 (m)	Ag2 (g/t)	Ag x m
Surface	ZG-20-06	214.50	218.50	4.00	9,346	37,384
Surface	ZG-20-22	101.00	113.50	12.50	1,363	17,038
Surface	ZG-20-05	182.00	184.50	2.50	4,705	11,763
Surface	ZG-20-04	165.00	170.50	5.50	2,046	11,253
Surface	ZG-20-05	403.00	405.00	2.00	3,640	7,280
Surface	ZG-20-09	467.50	471.50	4.00	1,275	5,100
Surface	ZG-20-25	159.00	162.50	3.50	1,174	4,109
Surface	ZG-20-19	155.50	159.00	3.50	863	3,021
Surface	ZG-20-22	78.50	81.50	3.00	965	2,895
Surface	ZG-20-06	290.50	293.50	3.00	930	2,790
Surface	ZG-20-04	107.00	110.00	3.00	890	2,670
Surface	ZG-20-02	285.50	295.00	9.50	266	2,527
Surface	ZG-20-25	34.00	37.50	3.50	631	2,209
Surface	ZG-20-04	95.00	97.00	2.00	987	1,974
Surface	ZG-20-19	183.00	193.00	10.00	194	1,940
Surface	ZG-20-04	328.50	333.00	4.50	428	1,926
Surface	ZG-20-01	422.00	426.50	4.50	396	1,782
UG	ZG-SF-20-11	15.5	17	1.50	1,170	1,755
Surface	ZG-20-22	181.50	183.50	2.00	877	1,754
Surface	ZG-20-06	229.00	230.00	1.00	1,624	1,624
Surface	ZG-20-01	473.00	474.50	1.50	1,000	1,500
Surface	ZG-20-22	24.00	27.00	3.00	498	1,494
UG	ZG-SF-20-14	57	60	3.00	496	1,487
Surface	ZG-20-05	194.50	196.00	1.50	855	1,283
Surface	ZG-20-19A	207.00	209.00	2.00	585	1,170
UG	ZG-SF-20-14	18	21	3.00	390	1,170
Surface	ZG-20-34	107.00	110.00	3.00	365	1,095
Surface	ZG-20-04	190.00	193.00	3.00	342	1,026

1 Holes were drilled at various angles; true widths are not known at this time

2 All assay results are above the cut-off grade of 75 g/t Ag

Figure 1 below shows the mineralized intercepts (Ag x thickness) from the 2020 drilling program together with three results received prior to 2020, ZG-RC-19-27, ZG-RC-19-18 and ZG-17-16, that underpin the 2020 exploration focus.

Figure 1 – Location of 2020 Exploration Drilling on Zgounder with 3 Historical Intercepts

See Figure 1

Completion of Operational & Maintenance Plan

The Corporation is amid a 12-month operation and maintenance turnaround plan at its Zgounder Silver Mine, three months ahead of schedule and under budget. Once completed, the Corporation expects to achieve nameplate capacity of 700 tpd or approximately one million ounces of silver production annually.

As a result of the operational changes implemented, recovery and availability are beginning to improve at both the flotation and cyanidation plants.

Building on 2020 momentum, Aya anticipates an active 2021 with key deliverables that include the Zgounder Silver Mine expansion feasibility study, a resource update early next year and continued drilling on the property.

Quality Assurance

For core drilling, all individual samples represent approximately one meter in length of core, which was halved. Half of the core is kept on site for reference, and its counterpart is sent for preparation and assaying to African Laboratory for Mining and Environment (“Afrilab”) in Marrakech, Morocco. All samples are analysed for silver, copper, iron, lead and zinc using Aqua regia and finished by atomic absorption spectroscopy (“AAS”). Samples grading above 200 g/t Ag are reanalysed using fire assaying.

Marc-Antoine Audet, Ph.D., P. Geo, Geological Consultant, is Aya Gold & Silver’s Qualified Person and has reviewed this press release for accuracy and compliance with National Instrument 43-101.

A word of appreciation to Aya’s geology team for successfully carrying out and going beyond our expectations with regard to the 2020 drilling program. Thanks are also due to our consultant Mr. Merouane Rachidi, P. Geo, Ph.D., for his initial contribution to the program.

About Aya Gold & Silver Inc.

Aya Gold & Silver Inc. is a publicly traded Canadian company focused on the operation, exploration, acquisition and development of silver and gold deposits. Aya is currently operating mining and milling facilities at its Zgounder Silver Mine, an 85%-15% joint venture between its subsidiary, ZMSM, and the Office National des Hydrocarbures et des Mines (“ONHYM”) of the Kingdom of Morocco.

Its mining portfolio also includes the Boumadine polymetallic deposit located in the Anti-Atlas Mountains of Eastern Morocco which is also a joint venture with ONHYM wherein Aya retains an 85% ownership. Additionally, the Corporation’s portfolio includes the Amizmiz and Azegour properties, both being 100% owned, with gold, tungsten, molybdenum and copper occurrences covering over 100 square kilometres in a historical mining district of Morocco.

For additional information, please visit Aya’s website at www.ayagoldsilver.com.

Or contact:

Benoit La Salle, FCPA FCA, President & CEO, [email protected]

Alex Ball,  VP, Corporate Development & IR, [email protected]

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified by the use of forward-looking terminology such as “strong”, “focus”, “secure”, “expanded”, “success”, “accelerates”, “future”, “growth”, “plan”, “expects”, “scheduled”, “objective”, “momentum”, “anticipates”, “continued”, “will”, “continue”, “provide”, “present”, “reasonable”, “established”, “has”, “demonstrate”, “potential”, “expect” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would” or “might”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information, including but not limited to: (i) volatile stock price; (ii) the general global markets and economic conditions; (iii) the possibility of write-downs and impairments; (iv) the risk associated with exploration, development and operations of mineral deposits including the accuracy of the current mineral reserve and mineral resource estimates of the Corporation (including, but not limited to, ore tonnage and ore grade estimates) and mine plans for the Corporation’s mining operations (including, but not limited to, throughput and recoveries being affected by metallurgical characteristics); (v) the risk associated with establishing title to mineral properties and assets including permitting, development, operations and production from the Corporation’s operations being consistent with expectations and projections; (vi) fluctuations in commodity prices and other risks and factors described or referred to in the section entitled “Risk Factors” in the MD&A of the Corporation and which is available at www.sedar.com, all of which should be reviewed in conjunction with the information found in this news release.

Although the Corporation has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Such forward-looking information has been provided for the purpose of assisting investors in understanding the Corporation’s business, operations and exploration plans and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is given as of the date of this press release, and the Corporation does not undertake to update such forward-looking information except in accordance with applicable securities laws.

Attachments

• Figure 1 – Zgounder 2020 best
• Aya Recap Dec 2020 Final

Alex Ball
Aya Gold & Silver Inc.
[email protected]

LAKE FOREST, Il, Dec. 22, 2020 (GLOBE NEWSWIRE) — Acquired Sales Corp. (OTCQX: AQSP) (www.AcquiredSalesCorp.com) announced today that its wholly-owned subsidiary Lifted Made, Zion, IL (www.LiftedMade.com), maker of hemp and hemp-derived products including CBD and delta 8 THC, has signed a five-year lease for a 11,238 square foot building located in Kenosha, Wisconsin, which represents a 94% increase in space that will be available for use by the rapidly growing hemp-derived cannabinoid products company. Under the terms of the net-net-net lease, Lifted Made will pay a base square foot charge of $6.13 per square foot per annum, with a 2% increase in rent each year during the term. The lease commencement date is January 1, 2021.

Under the terms of the lease, the tenant, Lifted Made, has the option to purchase the property at any time prior to December 31, 2025, and in any event, Lifted Made is obligated to purchase the property on or before that date.

Nicholas S. Warrender, AQSP’s COO and the CEO of Lifted Made, said, “Lifted Made is growing like crazy. We were just bursting at the seams at our 3,330 square foot facility in Zion, Illinois; so, in August, when the opportunity arose, we expanded into the bay next door to our rented unit, nearly doubling our footprint. But that additional space was still not enough. We needed more space for lab technicians, equipment, and manufacturing to keep up with the demand for our hemp-derived delta 8 THC and CBD products, and the space should allow us to handle inventory in relation to sales of tobacco-free nicotine pouches for SmplyLifted LLC, which we own 50-50 with SMPLSTC, Orange County, CA (www.SMPLSTCBD.com). Fortunately we found a perfect property in Kenosha, Wisconsin, and it could not be a better fit for our needs. The property has a great loading dock, we are in the process of building out different labs in the building for the production of various products, and there is more office space for our team. The interior’s just beautiful, and we’re excited to show it to our clients. Moreover, there is also air conditioning, which we don’t have in our Zion facility, and we’ll appreciate that during the hot summer days.”

The landlord of the property is 95^th Holdings, LLC, an entity owned by Nicholas S. Warrender, AQSP’s COO and the CEO of Lifted Made. The terms and conditions of the lease were negotiated on behalf of Lifted Made by Vincent J. Mesolella, the Lead Outside Director of Lifted Made’s publicly traded corporate parent Acquired Sales Corp., and the CEO of Providence, Rhode Island-based real estate development company REI, Inc.

Vincent J. Mesolella, Lead Outside Director of Acquired Sales Corp., commented: “I am very pleased that we have executed a lease/purchase agreement with 95^th Holdings, LLC. This new operating facility is expected to allow Lifted to expand operations in an orderly and more efficient manner. The work environment is always an important factor in worker satisfaction and morale. This facility will bring a real sense of pride to our workers. Most importantly, I believe the new facility does much to instill confidence in Lifted and create a very positive corporate image.”

About Lifted Made and Acquired Sales Corp.



Lifted Made was founded in 2015 by CEO Nicholas S. Warrender. In February 2020, Lifted Made became a wholly-owned subsidiary of publicly traded 



Acquired Sales Corp.



 (OTCQX ticker symbol 



AQSP



). Lifted Made makes many delta 8 THC and other hemp and hemp-derived products, all of which can be purchased online at 



www.LiftedMade.com



. Acquired Sales Corp. also owns 4.99% of CBD-infused beverage and products maker 



Ablis Holding Company



, and of craft distillers Bendistillery Inc. d/b/a 



Crater Lake Spirits



 and 



Bend Spirits, Inc.




,

 Bend, Oregon. Also, Lifted Made has a 50% membership interest in SmplyLifted LLC, which plans to sell tobacco-free nicotine pouches. For more information about Acquired Sales Corp., visit 



www.AcquiredSalesCorp.com



.

Cautionary Note Regarding Forward-Looking Statements Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such information includes the growth and profitability strategies, and future products and plans of Lifted Made and Acquired Sales Corp. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors which may cause or contribute to the actual results of Lifted Made’s and Acquired Sales Corp.’s operations or the performance or achievements of these companies differing materially from those expressed or implied by the forward-looking statements. Lifted Made and Acquired Sales Corp. undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain other factors, including the risk factors set forth in Acquired Sales Corp.’s filings with the Securities and Exchange Commission.

CONTACTS:

Lifted Made

Attn: Nicholas S. Warrender, CEO
Phone: 224-577-8148
Email: [email protected]
Website: www.LiftedMade.com

Acquired Sales Corp.

Attn: William C. “Jake” Jacobs, President and CFO
Phone: 847-400-7660
Email: [email protected]
Website: www.AcquiredSalesCorp.com 

Online consumer advocacy website,

PissedConsumer.com

, found that consumers using the site’s video interview option saw complaint resolutions at 5 times the rate of traditional consumer complaints

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Over a 3-year period U.S. consumer advocacy and customer complaints website, PissedConsumer.com, found video interviews increased the chance of consumers getting a satisfactory resolution 5 times more than with written consumer complaints.

Pissed Consumer launched its video interview feature in 2017. The videos amplify stand-out consumer reviews and “put a face” to some of the site’s customer complaints. This can help consumers get the attention of company representatives when standard reviews aren’t enough.

“Consumers are eager to participate in video interviews to share their stories,” said Joanna Simpson of PissedConsumer.com. “With video interviews, reviewers can more effectively share experiences that are difficult to explain in written reviews. Videos give them a true ‘voice’ when sharing interactions with companies, removing some of the usual anonymity behind consumer complaints which can make companies more receptive to offering solutions.”

Video interviews aren’t limited to consumer participants. Business owners can also take part.

For example, a business owner or company representative might use a video interview to share tutorials on how to use their products or explain recent product or service changes. This gives business owners the opportunity to address common customer questions or concerns before they become a problem, and before a consumer complaint is filed.

“Video interviews help create a more personal connection between consumers and business owners,” said Simpson. “That human touch can go a long way toward easing tensions with angry customers, both by fostering conversations that lead to resolutions and by keeping customers better-informed to minimize complaints in the first place.”

To learn more about video interviews, or to view all past consumer video interviews, visit the Pissed Consumer Interview page.

About PissedConsumer.com

PissedConsumer.com is a social consumer advocacy website where people can share consumer complaints and feedback with others. Visitors can also research companies, products, and services before making important purchasing decisions. Business solutions are available to help companies protect their reputations by responding to, and resolving, problems reported in consumer complaints.

For more information about PissedConsumer.com or its consumer video interviews, please visit www.PissedConsumer.com.

Contact:

Joanna Simpson, Media Relations
Email: [email protected]
Web: https://www.pissedconsumer.com/contact.html 

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2020 on Monday, December 28^th, 2020.

Management will host a conference call on Monday, December 28^th, 2020 at 4:30 pm Eastern Time to review financial results and provide an update on its clinical programs and corporate highlights. Following management’s formal remarks, there will be a question-and-answer session with equity analysts.

Conference Call / Webcast Information:

The live webcast of the conference call can be accessed online at https://wsw.com/webcast/cc/avxl16/1496358.

To join the conference call, live via telephone, interested parties within the U.S. should dial, toll-free, 1 (866) 939-3921 and international callers should dial 1 (678) 302-3550. Please use confirmation number 50061077, followed by the pound sign (#).

A replay of the conference call will also be available on www.anavex.com.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trials for Alzheimer’s disease and a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter,Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]

Investors and Media:

Clint Tomlinson
Email: [email protected]

GREAT NECK, N.Y., Dec. 22, 2020 (GLOBE NEWSWIRE) — Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance with the board approved dividend declared on October 26, 2020, a cash dividend of $0.11 per share will be paid to all shareholders of record on December 31, 2020. The dividend will be paid on January 15, 2021.

SOURCE:
Manhattan Bridge Capital
, Inc.

Contact:
Assaf Ran, CEO
(516) 444-3400

TORONTO, Dec. 22, 2020 (GLOBE NEWSWIRE) — Generation Mining Limited (TSX: GENM) (OTCQB: GENMF) (“Generation Mining” or the “Company”) is pleased to announce a fully subscribed non-brokered private placement of 4,295,000 common shares (the “Shares”) of the Company to be issued on a flow-through basis at a price of C$0.77 per Share for gross proceeds to the Company of C$3,307,150 (the “Offering”). Approximately 47% of the Offering will be subscribed to by a company controlled by Mr. Eric Sprott, making it the largest shareholder of the Company’s common shares.

“We are very grateful for the continued support of our shareholders, including Mr. Sprott, now our largest shareholder,” stated Jamie Levy, President and Chief Executive Officer. After closing this flow- through financing, Generation Mining will have more than $12 million in the bank. “This financing will allow Generation Mining to follow up on the results of our 2020 exploration season, while continuing to work on our feasibility study and permitting in 2021.”

Gross proceeds received from the sale of the Shares will be used to incur “Canadian exploration expenses” as defined in subsection 66.1(6) of the Income Tax Act (Canada) (the “Tax Act”) on the Company’s Marathon Property in the Province of Ontario, and renounced to subscribers in the Offering effective December 31, 2020. Such Canadian exploration expense will also qualify as a “flow-through mining expenditure” as defined in subsection 127(9) of the Tax Act.

A brokerage commission of 6% will be paid on a portion of the Offering.

An application has been filed with the Toronto Stock Exchange (“TSX”) for conditional approval of the Offering pursuant to Section 607 of the TSX Company Manual.

Closing of the Offering is expected to occur on or before December 31, 2020, and is subject to the satisfaction of certain conditions, including receipt of all applicable regulatory approvals including the approval of the TSX.

About Generation Mining Limited

Generation Mining’s focus is the development of the Marathon Palladium Project, the largest undeveloped platinum group metal Mineral Resource in North America. The Marathon property covers a land package of approximately 22,000 hectares, or 220 square kilometres. Generation Mining acquired a 51% interest in the Marathon Project from Sibanye Stillwater in 2019 and has since increased that ownership to 80%. Upon completion of the Feasibility Study, Sibanye Stillwater has certain back-in rights that can bring its interest in the property back to 51% (see the company’s press release of July 11, 2019, for more details). A feasibility study was started in the second quarter of 2020 with completion expected in the first quarter of 2021.

For further information please contact:

Jamie Levy
President and Chief Executive
Officer
(416) 640-2934
(416) 567-2440
[email protected]

Forward-Looking Information

This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address future production, reserve potential, exploration drilling, exploitation activities and events or developments that the Company expects are forward-looking statements. Although the Company believes the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in forward-looking statements. These include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. For more information on the Company, investors are encouraged to review the Company’s public filings at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.